Key Takeaways
- The AIM-NASH tool is expected to enhance the reliability and efficiency of clinical trials for new MASH treatments by reducing variability in measuring disease activity.
- The European Medicines Agency’s qualification of the tool means that the agency can accept evidence generated by the tool as scientifically valid in future applications from drug companies.
- A report by Datamonitor lists over 150 treatments for MASH in various phases of development.
- AIM-NASH is the first AI-based development methodology to be qualified by the EMA.
AIM-NASH, the first artificial intelligence (AI)-based pathology tool to be qualified by the European Medicines Agency for assessing drug candidates for metabolic dysfunction-associated steatohepatitis (MASH), could boost the market dynamics...
While only one drug has been approved in the US for the condition, the MASH space is crowded with a robust pipeline of drug candidates chasing a potentially lucrative market...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?